January 17, 2021
BlueSphere licensed technology from the lab of Mark Shlomchik, chair of the Department of Immunology at the Pitt Medical School, aimed at developing personalized T-cell therapies for cancer and other diseases. It had previously received a $10 million investment from UPMC Enterprises.
Read the investment coverage on the Pittsburgh Business Times (subscription may be required)